Bone Marrow Transplantation in Patients With Acute Leukemia In Cuba: Results From the Last 30 Years and New Opportunities Through International Collaboration

Blood and marrow transplantation (BMT) has been performed in Cuba for over 30 years with limited resources and without international relationships. Researchers from University of Illinois at Chicago and Hermanos Ameijeiras Hospital (HAH) in Havana collaborated on retrospectively analyzing 101 consecutive patients with adult acute leukemia who received BMT at HAH from June 1986 to January 2016. Of these, 82 had acute myeloid leukemia (AML) and 19 had acute lymphoblastic leukemia (ALL). BMT eligibility criteria included prior morphologic complete remission, no severe comorbidities, and age between 16 and 60 years. Patients with an HLA-matched donor received an allogeneic BMT, whereas the others received an autologous BMT. All patients received fresh stem cells from marrow (80%) or mobilized peripheral blood (19%). Of 82 patients with AML, 35 received an allogeneic (AML-allo) and 47 an autologous (AML-auto) BMT. Both groups had comparable median age (37 years) and follow-up of survivors. Overall survival (OS) was 34% in AML-allo and 38% in AML-auto. The transplant-related mortality rate was 40% in AML-allo and 17% in AML-auto, whereas the relapse-related mortality rates were 25% and 40%, respectively. Of the 19 patients with ALL, six received an allogeneic transplant. Of these, transplant-related mortality occurred in one patient and three died after disease relapse (OS, 33%). Of 13 patients who received autologous transplants, transplant-related mortality occurred in three and six died after disease relapse (OS, 31%). To our knowledge, this is the first scientific report on BMT performed in patients with acute leukemia in Cuba. The collaboration between University of Illinois at Chicago and HAH will further develop capacity building in research and implementation of new diagnostic and therapeutic strategies in Cuba.

© 2018 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License

INTRODUCTION

In low- and middle-income countries (LMICs), patients often have limited access to blood cancer care and still less access to bone marrow transplantation (BMT), because of lack of infrastructures, health care providers, or unaffordable costs. In contrast with many other LMICs, in Cuba, a country with approximately 11 million inhabitants and a low income per capita, the government provides free health care to every citizen, including cancer treatment and BMT. This procedure is available in five centers on the island: three in Havana and the others in Villa Clara and Holguín. However, allogeneic BMT (allo-BMT) is only available in Havana.

Although Cuba is planning to increase its BMT program, the total number of procedures is still low, due to multiple limiting factors. One of these is the difficulty in acquiring medicines, materials, and equipment, which has been affected by the economic embargo imposed on Cuba. Therapeutic agents commonly used in reduced-intensity conditioning regimens that would allow BMT in patients older than 60 years have not been available in Cuba. Peripheral blood hematopoietic cells can be only collected and used in the centers of the capital, because apheresis machines are not available outside Havana. Because stem cell cryopreservation systems are not available in the country, all transplantations must be carried out using fresh hematopoietic...
progenitor cells. Therefore, in autologous transplants, the stem cells are collected from the patient and kept at 4°C for 48 to 72 hours, thus preventing the possibility of using conditioning regimens lasting longer than 3 days.\(^3\) Another limiting factor has been the inability of Cuban centers to access international marrow-donor registries for patients lacking a matched sibling and, until a few years ago, to establish scientific exchanges with centers in the United States and Europe.

The Hermanos Ameijeiras Hospital (HAH) in Havana is the largest tertiary health care institution for adult patients in Cuba. The Hematology Service includes eight hematologists who attend 27 inpatient beds. Of these beds, four are dedicated only to acute leukemia and three to ongoing BMT. Despite the cited difficulties and the limited resources, the HAH BMT program started in 1986 and has been performing, on average, 15 to 18 autologous or matched related-donor allogeneic BMTs yearly (C. Hernández Cruz, personal communication, 2015).

In 2016, the BMT Program at the University of Illinois at Chicago (UIC) initiated collaborating with the BMT Program at HAH. Main objectives of this collaboration have been (1) training a Cuban physician in novel BMT strategies such as reduced-intensity allogeneic stem cell transplantation, autologous transplant in elderly patients with myeloma, and use of haploidentical donors with nonmyeloablative regimens; (2) organizing a training conference in Havana for Cuban physicians attending BMT units throughout the country; and (3) building research capacity and supporting analysis of clinical outcome in BMT in Cuba.

The first objective was achieved in 2016 by hosting a member of the HAH BMT staff for 3 months as an observer of all the components of the UIC BMT Program. Upon his return, HAH officially implemented a haploidentical transplant program and started performing BMT in patients older than 60 years. The second objective was achieved by co-organizing the BMT conference in Havana in October 2017, where updated protocols and results of BMT were presented by members of UIC and HAH to more than 70 participants who came from different parts of the island. The third objective was initially addressed by collaborating on the design and analysis of the retrospective study presented here.

**PATIENTS AND METHODS**

A retrospective study by chart review was approved by the HAH Institutional Review Board to analyze the results of BMT from June 1986 to January 2016 in patients with adult acute leukemia who underwent BMT. Data collection was limited by the few BMT details in the records stored from decades ago and by scarcity of clinical information on follow-up encounters for many patients. However, the Cuban BMT team was able to obtain information on diagnosis, patients’ sex and age, type of transplant, source of stem cells, overall survival (OS), and rates of transplant-related mortality (TRM) versus relapse-related mortality.

A total of 101 consecutive cases were analyzed. Eligibility criteria for autologous and allogeneic BMT included age older than 16 years and younger than 60 years, achievement of morphologic complete remission, and no severe organ impairment before BMT. Patients who had an HLA-matched related donor received an allo-BMT, whereas all the others received an autologous BMT (auto-BMT). Cytogenetic and molecular analyses at diagnosis were not performed in most patients because those analyses were not yet available for patients receiving their diagnosis in the 1980s and because these studies are still not available routinely in Cuba.

Transplants

In allo-BMT, matched related-donor selection was based on HLA class I and II matching. From 1985 to 2010, class I HLA A and B antigens were typed by serologic assays, and class II DR antigen was tested by mixed leukocyte reaction and serologic assays. In 2011, low-resolution molecular typing was introduced (ie, HLA, A, B, C, DRB1, and DQB1), and since 2014, high-resolution molecular HLA typing is available. In both auto- and allo-BMT, the sources of hematopoietic stem cells were bone marrow or peripheral blood stem cells. These were infused fresh within 72 hours after collection. Conditioning regimens used in auto- and allo-BMT were standard myeloablative oral busulfan and intravenous cyclophosphamide (Cy), total-body irradiation (TBI) and Cy or TBI, Cy, and VP16.\(^4,5\) In these regimens, Cy was administered in 1 day, and in patients undergoing autologous BMT, this would be infused on the same day of marrow
harvest. TBI, 10 Gy, was initially administered as single fraction and, for most patients, in two daily 5-Gy fractions. In allo-BMT, graft-versus-host disease (GVHD) prophylaxis was standard cyclosporine-A and methotrexate administered on days 1, 3, 6, and 11 after transplant.

Statistical analysis
Cumulative incidence and survival were analyzed using Kaplan-Meier statistics. Differences within AML and ALL groups were analyzed by $t$ test or $\chi^2$ test. Statistical tests were performed using GraphPad Prism, version 7.0 (GraphPad Software, San Diego, CA).

RESULTS
Transplant policy for auto- and allo-BMT in patients with AML

Patients’ characteristics related to age, diagnosis, stem cell source, and time of follow-up are listed in Table 1. Because of the lack of cryopreservation facilities in Cuba, 90% of the transplantations were performed using fresh marrow cells, and 10% were performed using peripheral blood stem cells. In auto-BMT, the conditioning regimens were administered within 72 hours from stem cell collection. Of 101 patients, 83 had AML. Of these, 35 received an allogeneic (AML-allo) and 47 an autologous (AML-auto) BMT. No differences were recorded between patients’ characteristics receiving allo- or auto-BMT. The median age of the patients was 37 (range, 22 to 54) years in the AML-allo group and 36 (range, 18 to 58) years in the AML-auto group. Of 19 patients with ALL, six received an allogeneic (ALL-allo) and 13 received an autologous (ALL-auto) BMT. The median age in the two groups was 36 years (range, 18 to 47 years) and 27 years (range, 17 to 34 years), respectively. Because of the policy established at HAH, all eligible patients with ALL underwent either auto- or allo-BMT only on the basis of matched related donor availability.

Comparable Survival in auto- and allo-BMT

The median follow-up for surviving patients in the study is 72 months (range, 1 to 206 months). Median survival for patients with AML is 69 months (range, 1 to 206 months) and 92 months (range, 15 to 276 months) for patients with ALL ($P = .4$). The limited follow-up is in part due to the policy that patients from outside Havana return to their primary hematologist within 1 to 2 years after transplantation, or, in some cases, because patients left Cuba soon after transplantation for personal or logistic reasons. Incidence of acute and chronic GVHD was not analyzed because these data were not available in the records. However, deaths related to GVHD, as well as infections or organ dysfunction after transplantation had been all identified as causes of TRM.

Of the 82 patients with AML who received BMT, 38% of those receiving an auto-BMT and 34% of those receiving an allo-BMT survived. However, auto-BMT was associated with higher relapse-related mortality but a lower TRM rate, compared with those receiving allo-BMT (Table 2). Of 13 ALL-auto cases, nine patients died: Six died after disease relapse and TRM occurred in three (OS, 31%), whereas of six patients who underwent ALL-allo, three died after disease relapse and TRM occurred in one (OS, 33%; Table 2). OS curves for patients with AML and those with ALL, as well for recipients of allogeneic and autologous hematopoietic BMT in each group are shown in Figure 1. These results show comparable outcome in auto- and allo-BMT in adult patients with acute leukemia who underwent transplantation in Havana.

Table 1. Characteristics of Patients With Acute Leukemia Who Received Autologous or Allogeneic Bone Marrow Transplant at Hermanos Ameijeiras Hospital from 1986 to 2016

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>101</td>
</tr>
<tr>
<td>AML</td>
<td>82</td>
</tr>
<tr>
<td>ALL</td>
<td>19</td>
</tr>
<tr>
<td>Age at AML diagnosis, median (range), years</td>
<td>36 (18-47)</td>
</tr>
<tr>
<td>Age at ALL diagnosis, median (range), years</td>
<td>27 (17-34)</td>
</tr>
<tr>
<td>Auto-SCT</td>
<td>60</td>
</tr>
<tr>
<td>Allo-SCT</td>
<td>41</td>
</tr>
<tr>
<td>Source of stem cells, %</td>
<td></td>
</tr>
<tr>
<td>Bone marrow</td>
<td>80</td>
</tr>
<tr>
<td>PBSC</td>
<td>19</td>
</tr>
<tr>
<td>Cord blood</td>
<td></td>
</tr>
<tr>
<td>Follow-up of surviving patients, median (range), months</td>
<td>72 (1-276)</td>
</tr>
</tbody>
</table>

Abbreviations: ALL, acute lymphoblastic leukemia; Allo, allogeneic; AML, acute myeloid leukemia; Auto, autologous; PBSC, peripheral blood stem cell; SCT, stem cell transplant.
Table 2. Results of Autologous and Allogeneic Bone Marrow Transplantation in Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia at Hermanos Ameijeiras Hospital from 1986 to 2016

<table>
<thead>
<tr>
<th>Transplant Type</th>
<th>No.</th>
<th>OS (%)</th>
<th>TRM (%)</th>
<th>RRM (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML-auto</td>
<td>47</td>
<td>38</td>
<td>17</td>
<td>40</td>
</tr>
<tr>
<td>AML-allo</td>
<td>35</td>
<td>34</td>
<td>40</td>
<td>25</td>
</tr>
<tr>
<td>ALL-auto</td>
<td>13</td>
<td>31</td>
<td>23</td>
<td>46</td>
</tr>
<tr>
<td>ALL-allo</td>
<td>6</td>
<td>33</td>
<td>17</td>
<td>50</td>
</tr>
</tbody>
</table>

NOTE: Differences between AML-auto and AML-allo, or ALL-auto and ALL-allo were compared by χ² test and were not statistically significant.

Abbreviations: ALL-auto, autologous bone marrow transplant in patients with acute lymphoblastic leukemia; AML-auto, autologous bone marrow transplant in patients with acute myeloid leukemia; AML-allo, allogeneic bone marrow transplant in patients with acute myeloid leukemia; ALL-auto, autologous bone marrow transplant in patients with acute lymphoblastic leukemia; ALL-allo, allogeneic bone marrow transplant in patients with acute lymphoblastic leukemia; AML-auto, autologous bone marrow transplant in patients with acute myeloid leukemia; OS, overall survival; RRM, relapse-related mortality; TRM, transplant-related mortality.

DISCUSSION

To our knowledge, this is the first Cuban experience of BMT reported outside of Cuba and is a useful source of information to many investigators to better understand the policies and outcomes of patients with leukemia in a country with limited resources and international connections. The collaboration between UIC and HAH in Havana has created a new opportunity for building capacity in research, clinical strategy development, and education. A recent report on emerging BMT centers in Central or South America did not include any data from Cuba; however, it showed that in other Latin American countries, there is a lower rate of BMT compared with North America. Socioeconomic factors such as low per capita gross national income, low per capita health care expenditure, and low BMT team density were reported as possible explanations of their findings. We envision that despite the limited financial resources, other factors will likely contribute to the expansion of BMT in LMIC. In fact, our experience, like those of others in southeast Asia, suggests the following: (1) an international network allows LMIC teams to learn and build comprehensive transplant programs; (2) use of generic drugs, fast cryopreservation procedures, or outpatient-based BMT can lower the cost of BMT; (3) increasing knowledge of reduced-intensity BMT regimens will allow LMIC to expand the age of patients receiving BMTs while reducing costs; and (4) the increasing evidence that haploidentical BMT using posttransplant high-dose Cy has results comparable to those of unrelated-donor BMT without major complications also in LMIC will give a low-cost transplant opportunity to many patients. Cuba, in particular, will certainly benefit from expanding a haploidentical BMT program because transplants from unrelated donors are very rare in Cuba due to the disconnection from international marrow-donor registries.

The recent collaboration between UIC and HAH has been focused on building capacity by supporting Cuban investigators in establishing new protocols, such as haplotransplant or autologous transplant in patients older than 65 years, and collecting data and developing a research project that will allow them to analyze and learn from their results.

The retrospective study presented here, despite being limited by relatively few patients and lack of detailed information on GVHD or infectious complications, also represents a rare opportunity to study the outcome of BMT in a country where the high cost of the procedure is not a limiting factor for patients and families. Unlike in many other LMIC, the Cuban government provides full coverage of health care services to Cuban citizens. In fact, Cuban patients with acute leukemia and with an HLA-matched sibling have been offered a standard allo-BMT for over 30 years, whereas for patients who did not have a compatible related donor, an auto-BMT was performed as consolidation chemotherapy, per HAH policy. This approach has allowed us to analyze retrospectively different comparable groups of patients selected only on the basis of donor availability. The similar survival rates we report in auto- and allo-BMT could likely be due to a relatively short follow-up, but these rates could also point to the fact that patients with AML were not selected by disease risk. Physicians in Cuba are now gradually introducing a treatment algorithm in acute leukemias (BMT vs chemotherapy alone) according to their cytogenetic and molecular profile as these techniques become more accessible. However, this still constitutes a formidable challenge...
Table 3. Goals of BMT in Low- and Middle-Income Countries (LMICs) and Opportunities for Capacity Building and Implementation—Based Collaboration Between Hermanos Ameijeiras Hospital and University of Illinois at Chicago

<table>
<thead>
<tr>
<th>Incremental Goals of GlobalBMT in LMICs</th>
<th>Areas of Research Collaboration and Capacity-Building Initiatives in Havana</th>
</tr>
</thead>
<tbody>
<tr>
<td>Easy access to BMT</td>
<td>Socioeconomic determinants and health care policies</td>
</tr>
<tr>
<td>Disease risk assessment</td>
<td>Immunologic and molecular diagnostic techniques</td>
</tr>
<tr>
<td>Low-cost and high-quality BMT procedures</td>
<td>Use of generic drugs in BMT and low-cost stem cell cryopreservation</td>
</tr>
<tr>
<td>Quality management</td>
<td>Integrated monitoring of complications and surveillance</td>
</tr>
<tr>
<td>Data collection</td>
<td>Institutional review board and data collection</td>
</tr>
<tr>
<td>Clinical research</td>
<td>Clinical trial team development</td>
</tr>
</tbody>
</table>

Abbreviation: BMT, bone marrow transplantation.

We conclude that centers in high-income countries, such as UIC, can have substantial impact in addressing disparities in LMIC in BMT access when focused on building capacity and implementation of high-quality and low-cost clinical programs and research infrastructure (Table 3).

DOI: https://doi.org/10.1200/JGO.18.00109
Published online on jgo.org on November 30, 2018.

AUTHOR CONTRIBUTIONS
Conception and design: José Carnot Uria, Calixto Hernández Cruz, Wilfredo Torres Yribar, Concepción del Castillo Carrillo, Yusaima Rodríguez Fraga, Kali Cepero Llauger, Karen Sweiss Pritesh R. Patel, Damiano Rondelli
Financial support: Ibis K. Pardo Ramírez
Administrative support: Calixto Hernández Cruz, Wilfredo Torres Yribar, Ibis K. Pardo Ramírez, Damiano Rondelli
Provision of study material or patients: José Carnot Uria, Wilfredo Torres Yribar, Calixto Hernández Cruz, Jorge Muñío Perurena, Concepción del Castillo Carrillo, Ibis K. Pardo Ramírez, Aliette García
Collection and assembly of data: José Carnot Uria, Calixto Hernández Cruz, Jesús Diego de la Campa, Concepción del Castillo Carrillo, Yusaima Rodríguez Fraga, Julio A. López Silva, Kali Cepero Llauger, Aliette García García, Damiano Rondelli
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/fic or ascopubs.org/jco/site/ifc.

José Carnot Uria
No relationship to disclose

Calixto Hernández Cruz
No relationship to disclose

Jorge Muñío Perurena
No relationship to disclose

Wilfredo Torres Yribar
No relationship to disclose

Jesús Diego de la Campa
No relationship to disclose

Concepción del Castillo Carrillo
No relationship to disclose

Yusaima Rodríguez Fraga
No relationship to disclose

Julio A. López Silva
No relationship to disclose

Kali Cepero Llauger
No relationship to disclose

Ibis K. Pardo Ramírez
No relationship to disclose

Aliette García García
No relationship to disclose

Karen Sweiss
No relationship to disclose

Pritesh R. Patel
Consulting or Advisory Role: Celgene

Speakers’ Bureau: Janssen, Amgen, Celgene

Damiano Rondelli
Consulting or Advisory Role: Incyte

Downloaded from ascopubs.org by 201.220.215.14 on October 28, 2019 from 201.220.215.014
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
Affiliations
José Carnot Uria, Calixto Hernández Cruz, Jorge Muñío Perurena, Wilfredo Torres Yribar, Jesús Diego de la Campa, Concepción del Castillo Carrillo, Yasalma Rodríguez Fraga, Julio A. López Silva, Kali Cepero Llauag, Ibis K. Pardo Ramírez, Aliette García García, Universidad Hermanos Ameijeiras Hospital, Havana, Cuba; and Karen Sweiss, Pritesh R. Patel, and Damiano Rondelli, University of Illinois at Chicago, Chicago, IL.

Support
Supported by University of Illinois Center for Global Health.

Prior Presentation

REFERENCES